Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn’s disease

Adi Lahat1,2*, Uri Kopylov1,2, Sandra Neuman1,2, Nina Levhar1,2, Doron Yablecovitch1,2, Benjamin Avidan1,2, Batia Weiss2,3, Shomron Ben-Horin1,2†, Rami Eliakim1,2† and on behalf of the Israeli IBD research Network (IIRN)

Abstract

Background: Helicobacter pylori (HP) infection is present in about 50% of the global population, and is associated with chronic gastritis, peptic disease and gastric malignancies. HP prevalence in Crohn’s disease (CD) patients was shown to be low compared to the general population, and its influence on disease activity is yet to be determined. Our aims were to determine the prevalence of HP in a selected group of CD patients with quiescent disease, and to assess the influence of its eradication on disease activity and endoscopic and laboratory activity measures.

Methods: Consecutive CD patients with quiescent disease underwent meticulous disease evaluation with MR enterography (MRE), video capsule endoscopy (VCE), CRP, fecal calprotectin and CDAI. All patients were tested for the presence of HP using stool antigen detection kit. Patients infected with HP were offered eradication treatment with sequential therapy. HP eradication was confirmed using urease breath test and stool antigen test. The influence of HP eradication on disease activity was assessed.

Results: Out of 56 patients enrolled, six patients (10.7%) had HP infection. Of them, five patients had gastro-duodenitis per VCE. All HP positive patients were offered eradication treatment and underwent successful eradication. Notably, 23 (50%) of patients had proximal disease per VCE, most of them (78%) were HP negative. CDAI, CRP, fecal calprotectin and VCE Lewis inflammatory score did not change significantly following HP eradication, Gastric findings on VCE were not impacted by HP eradication.

Conclusions: The prevalence of HP infection in patients with quiescent CD is relatively low. Eradication of the bacteria did not significantly change neither disease activity measures nor the presence of gastro-duodenitis per VCE, suggesting it might be part of proximal CD. The influence of HP on CD activity merits further investigation.

Keywords: Crohn's disease, Helicobacter pylori, Video capsule endoscopy, Prevalence, Eradication

Background

Helicobacter pylori (HP) infection is one of the most prevailing global pathogens in humans, and can be detected in 50% of the world's population [1]. Its prevalence varies considerably in association by geography, ethnicity, age, and socioeconomic factors.

This Gram-negative bacterium causes chronic inflammation in the gastric mucosa, which leads to atrophic and metaplastic changes. Thus, HP infection is associated with chronic gastritis, peptic disease and gastric malignancies [2, 3]. Crohn's disease (CD) is a chronic inflammatory condition that can affect the gastrointestinal system from the mouth to the anus. Inflammation is transmural, and therefore may be cause internal abscesses, fistula between adjacent organs, spontaneous viscous perforations and fibrotic strictures. The disease may cause significant morbidity and diminished life quality [4–8]. Disease behavior is characterized by periods of flare-ups with active symptomatic disease and periods of remission [9]. Over the years, many epidemiological
studies showed low incidence of HP infection in patients with CD [10–18].

A recent meta-analysis demonstrated negative association between HP infection and CD with OR of 0.38 (95% CI 0.31 to 0.47, p value < 1e-10) [19].

The reason for that negative association is yet to be determined. One hypothesis suggests that medications used for CD treatment may eradicate HP. Another suggestion along the same line is that CD mucosal alterations might prevent HP colonization [14, 15, 18–22]. An alternative argument suggests a protective effect for HP infection from the occurrence of CD.

CD is categorized by selectively activation of type 1 T helper lymphocyte (Th1) and Th17-related cytokines involved in innate immunity (interleukin (IL) 12, IL-23, IL-27) [23]. HP was shown to produce IL-18 which causes accumulation of tolerogenic dendritic cells and highly suppressive regulatory T cells (Tregs) that help suppress the inflammatory process [24].

High frequency of gastritis and duodenitis was described in CD patients with no association to HP infection [20–22]. However, data assessing the effect of HP infection and eradication on proximal disease and on disease activity in patients with CD is scarce.

Thus, in our study we focused on patients with known quiescent Crohn’s disease that were prospectively evaluated for disease activity measures before and after HP eradication.

Methods
Patient population
Study population consisted of adult (>18 years) CD patients with known small bowel Crohn’s disease in clinical remission, as determined by the validated Crohn’s disease activity index (CDAI) of <150, or patients suffering from mild disease symptoms, presented by CDAI of 150–220. All patients included were treated with stable medication doses and on corticosteroid-free remission for 3–24 months. Patients maintained on constant treatment throughout study duration.

Patients that were unable to provide informed consent were excluded from the study. Patients with severe comorbidities or with any condition that will prevent them from swallowing VCE (difficulty in swallowing, history of aspirations or dysphagia, known or suspected intestinal obstruction or severe bowel strictureing) or undergoing MRE (claustrophobia or implanted metal objects or cardiac pacemaker) were excluded as well.

Imaging studies
All patients underwent an MRE upon enrollment. MR image acquisition was performed using a previously described protocol [25]. A patency capsule (PC) test was performed in all patients with active small bowel disease detected on MRE. If the PC was not expelled from the small bowel within 30 h, the patient was withdrawn from the study. Mucosal inflammation was quantified using the Lewis inflammatory score (LS). Active inflammation was defined as a segmental Lewis score of ≥135 [26]. A board-certified gastroenterologist with over 10 years of experience in capsule endoscopy read the capsule videos. Gastric and duodenal findings were described for each study.

Inflammatory biomarkers and disease activity measures
Fecal calprotectin, CRP and complete blood count (CBC) were measured routinely every 3 months. Fecal calprotectin levels were measured using the Quantum blue calprotectin kit (BÜHLMANN Laboratories AG, Basel, Switzerland). The reported value range is 30 to 300 μg/g. Levels above 100 μg/g were considered positive. CRP levels were considered elevated if > 5 mg/l.

Patients underwent physician’s evaluation and CDAI assessment for disease activity every 3 months.

HP assessment and treatment
All patients were tested for the presence of HP using stool antigen detection kit as part (CerTest H. pylori one step card test, Certest Biotec S.L. Zaragoza, Spain). Stool antigen test was chosen for HP detection since this method is noninvasive and most importantly is not influenced by antibiotics or Proton Pump Inhibitors (PPI) treatment. This kit has a sensitivity of >94%, specificity of >99% and Positive predictive value (PPV) of >99% for HP detection. Patients infected with HP were offered eradication treatment with sequential therapy consisted of 5 days of esomeprazole (40 mg) and amoxicillin (1000 mg) twice daily, followed by 5 days of esomeprazole (40 mg), clarithromycin (500 mg) and Tinidazole (500 mg) twice daily [27]. Notably, sequential therapy is the standard of care for patients infected with HP in our institution. Prior to eradication treatment patients received detailed explanation regarding HP infection implications and the importance of compliance and adherence to treatment. HP eradication was confirmed using urease breath test and stool antigen detection kit 4 weeks following eradication treatment completion.

The impact of HP eradication on disease activity and degree of proximal small bowel inflammation was assessed using the disease activity measures specified above, 8 weeks after eradication conformation.
Statistical analysis
Descriptive statistics were presented as means ± standard deviations for continuous variables and percentages for categorical variables. Categorical variables were analyzed by Chi Square/Fisher's exact test and continuous variables-by T-test/Mann Whitney test, as appropriate. \( P < 0.05 \) was considered significant. All computations were performed with the MedCalc Software (Marieke, Belgium).

Results
Fifty six patients were included in the study. Patients’ demographic data and disease characteristics are shown in Table 1. None of the patients was tested for HP prior to this study. A schematic graph of study design is shown in Fig. 1.

Out of all patients included, only six patients (10.7%) were infected with HP. Of them, five patients had gastro-duodenitis per VCE and one had no proximal disease and no upper GI symptoms. All HP positive patients were offered eradication treatment with sequential therapy detailed above. All infected patients agreed to receive eradication treatment, and all treated patients underwent successful eradication, as was confirmed by a negative urease test and negative stool antigen test. Thus, a 100% eradication rate was achieved.

Notably, 23 (50%) of patients had proximal disease per VCE, most of them (78%) were HP negative.

Four weeks after a verified eradication, a repeated evaluation of disease activity was performed. Physical examination, CBC, CRP was performed and CDAI was calculated. Capsule endoscopy was ingested as well 12 weeks following eradication. Disease activity measures before and 12 weeks following HP eradication in all patients treated was compared, and are shown in Table 2. A separate analysis was performed only for patients who had gastro-duodenitis per VCE before HP eradication. Results are shown in Table 3.

As shown in Tables 2 and 3, all disease activity measures as well as anatomical disease distribution (measured by VCE Lewis inflammatory score) were unchanged following HP eradication. Hence, HP eradication had no influence on disease activity.

Figures 2a, b and 3a, b show active CD in the proximal digestive system demonstrated by mucosal erosions in stomach and duodenum - unchanged before and after eradication treatment, respectively.

Discussion
HP infection is one of the most prevalent infectious diseases worldwide. However, in CD patients its prevalence was shown to be lower than in general population [10–18]. The reason for that remains to be determined, as is the mutual impact of CD and HP infection on patients’ symptoms, severity of the disease and on disease distribution. In the current study, we initially assessed the prevalence of HP infection in a homogenous group of CD patients with quiescent disease, and then tried to assess prospectively the impact of HP eradication on disease activity measures and on anatomical inflammatory distribution.

In agreement with data in the literature [10–18], HP infection rate was low among our patients’ group, with only 11% of patients tested positive to HP. The current prevalence of HP infection in Israel is unknown, yet data from 2002 [28] suggest a 60% prevalence among the general population in Israel. Thus, even if we assume a possible reduction in HP infection in the general population during the last decade, HP infection among CD patients is still significantly low. Notably, none of our patients was tested for the presence of HP before entering the study, and consequently none was ever treated for HP eradication. Therefore, we believe that our data reflects the true prevalence of HP infection in CD patients.

All the patients who tested positive for HP were offered eradication treatment, though one of them was asymptomatic. Since HP is a well known carcinogen with a strong proven relation to gastric malignancy [2, 3], we decided to offer eradication treatment to all infected patients.

In order to achieve maximal eradication rates patients were treated with a 10 day sequential therapy, which was shown to have eradication success of up to 94% [29].

In addition, at treatment initiation patients received individual consultation with emphasis on the importance

| Table 1 Patients’ demographic data and disease characteristics |
|---|---|---|
| **Male/female** | 30/26 | 53.6/46.4 |
| **Age at diagnosis (years)** | 26 ± 11 |
| **Disease duration (years)** | 6 ± 5 |
| **Clinical remission** | 52 | 92.3 |
| **Smoking status** | **current** | 11 | 19.6 |
| | **never smoked** | 36 | 64.3 |
| | **past smoking** | 9 | 16.1 |
| **Previous surgery** | 9 | 16.1 |
| **Perianal disease** | 13 | 23.2 |
| **Current medical treatment** | **Thiopurine** | 25 | 44.6 |
| | **Anti-TNF** | 21 | 37.5 |
| | **Combined anti-TNF + thiopurine** | 7 | 12.5 |
| **No medical treatment** | 11 | 19.6 |
of compliance and adherence to the offered treatment. Eradication was verified both with urease breath test and with stool antigen detection kit. Using this meticulous treatment option, we managed to reach a 100% eradication rate.

Obviously, since our treatment group consisted of 6 patients only, the results are underpowered to assess treatments' efficacy. However, we believe that the combination of a high-efficacy eradication protocol and highly motivated patients with high compliance rates probably lead to this unusually high eradication rate.

Eradication was verified using breath test and stool antigen kit 4 weeks following treatment completion [30]. Eight weeks following eradication verification, patients underwent repeated disease evaluation, including VCE. Data in literature support repeated endoscopy for peptic disease 4 weeks following HP eradication treatment [31]. Therefore, we postulated that 8 weeks following eradication verification and 12 weeks following end of eradication treatment is appropriate for reevaluation, assuming that all mucosal damage caused by HP would be healed.

Our results show no improvement in proximal disease or in disease measures following HP eradication. Hence, CDAI, CRP and fecal calprotectin levels did not differ significantly after HP eradication, implicating disease activity was unchanged following eradication. Moreover,

### Table 2 Disease activity measures in all HP positive patients before and after eradication (n = 6)

| Disease measures   | Before eradication | After eradication | p     |
|--------------------|--------------------|-------------------|-------|
| CDAI               | 27.5 ± 21.25       | 22.83 ± 28.25     | NS    |
| CRP                | 1.17 ± 0.82        | 2.97 ± 4.7        | NS    |
| Fecal calprotectin | 75 ± 79.37         | 112.17 ± 123.2    | NS    |
| Lewis Score        | 425 ± 334.29       | 564.83 ± 529.46   | NS    |

NS non-significant

### Table 3 Disease activity measures in HP positive patients with gastroduodenitis on VCE before and after eradication (n = 5)

| Disease measures   | Before eradication | After eradication | p     |
|--------------------|--------------------|-------------------|-------|
| CDAI               | 23.18 ± 25.6       | 30.91 ± 25.2      | NS    |
| CRP                | 1.218 ± 0.9        | 5.12 ± 3.398      | NS    |
| Fecal calprotectin | 85 ± 85.25         | 74.6 ± 71.57      | NS    |
| Lewis Score        | 357.33 ± 465       | 587.995 ± 589.8   | NS    |

NS non-significant

---

**Fig. 1 Study design**
the VCE Lewis inflammatory score, as a measure of disease activity and distribution was showed no statistically significant improvement following HP eradication as well. These results were unchanged after separate sub analysis of patients with gastro-duodenitis per VCE.

These data implicates that the proximal disease as well as disease activity was unrelated to HP. To the best of our knowledge, up to date, no study addressed disease activity measures pre versus post HP eradication in CD patients.

In our study, 50% of patients had gastro-duodenitis per VCE. These results are in agreement with previous studies that showed an increased prevalence of gastro-duodenitis disease in CD patients with no association to HP infection [20–22].

Our study has several limitations. First, our cohort of patients was relatively small. Therefore, due to the low prevalence of HP infection in CD patients, the number of HP infected patients was very low. The small number of patients included might affect the applicability of our results.

Another theoretical drawback of our study is a selection bias- only patients with quiescent disease were included, thus patients with active CD might have had different results.

However, we feel that our data supports the evidence showing high incidence of gastroduodenitis in patients with quiescent CD, unrelated to HP infection.

Conclusions
HP infection in patients with quiescent CD is lower than in the general population, and reaches 11%. Eradication of the bacteria did not change significantly neither disease measures nor the presence of gastro-duodenitis per VCE, suggesting it might be part of proximal CD. The influence of HP on CD activity merits further investigation.
Abbreviations
CBC: Complete blood count; CD: Crohn’s disease; CDAI: Crohn’s disease activity index; HP: Helicobacter pylori; IL: Interleukin; LS: Lewis inflammatory score; MRE: MR enterography; PC: Paracystitis capsule; PPI: Proton pump Inhibitor; Th1: Type 1 T Helper lymphocyte; VCE: Video capsule endoscopy

Acknowledgements
The following physicians have collaborated in this research: Iris Dotan, Henit Yanai (Tel Aviv Medical Center); Yehuda Chowers (Rambam Health Campus), Marianne M. Amitai (Chaim Sheba Medical Center).

Funding
The study was partially supported by a generous grant from the Leona M and Harry B. Helmsley Charitable Trust. This generous financial support enabled data collection.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available since it contains identifying patients’ data but are available from the corresponding author on reasonable request.

Authors’ contribution
AL – conception and design, data collection, manuscript preparation, revision and drafting. UK – acquisition of data. BW – acquisition of data. SN – acquisition of data. DY – acquisition of data. BA – acquisition of data. BW – acquisition of data. SBH – manuscript revising and data interpretation. RE – manuscript revising and data interpretation. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests relevant to this study.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the Chaim Sheba Medical Center ethics committee. All patients signed a written informed consent.

Author details
1Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Tel Hashomer, Israel. 2Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3Edmond and Lily Safra Children’s Hospital, Tel Hashomer, Israel.

Received: 30 June 2016 Accepted: 10 February 2017
Published online: 13 February 2017

References
1. World Gastroenterology Organisation Global Guidelines Helicobacter pylori in developing countries, August 2010. Available at: www.worldgastroenterology.org/UseFiles/file/guidelines/helicobacter-pylori-eng-2010.pdf. Last Accessed 10 Nov 2015
2. Sonnenberg A. Review article: historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther. 2013;38:329–42.
3. Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014;20(18):5191–204.
4. Love JR, Irvine EJ, Fedorak RN. Quality of life in IBD. J Clinical Gastroenterol. 1992;14:15–9.
5. Casellas F, Arenas JL, Baust JD, Vázquez J, García N, Gelabert J, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488–96.
6. Rubin GP, Hugnin AP, Chinn DJ, Dwarakanath D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther. 2004;19:529–35.
7. Casellas F, López-Vivas J, Badia X, Malagelada JR. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol. 2001;13:567–72.
8. Canavan C, Abrams KR, Hawthorne B, Drossman DA, Maybery JF. Long-term prognosis in Crohn’s disease: factors that affect quality of life. Aliment Pharmacol Ther. 2006;23:377–85.
9. Lattela G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 2012;18:3790–9.
10. Sonnenberg A, Genta RM. Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:469–76.
11. Xiang Z, Chen YP, Ye YF, Ma KF, Chen SH, Zheng L, et al. Helicobacter pylori and Crohn’s disease: a retrospective single-center study from China. World J Gastroenterol. 2013;19:4576–81.
12. Pearce CB, Duncan HD, Timmis L, Green JR. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:439–43.
13. El-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut. 1994;35:1385–8.
14. D’Incà R, Sturionlo G, Cassaro M, di Pace C, Longo G, Callegari I, et al. Prevalence of upper gastrointestinal lesions and Helicobacter pylori infection in Crohn’s disease. Dig Dis Sci. 1998;43:988–92.
15. Parente F, Molteni P, Bollani S, Maconi G, Vago L, Duca PG, et al. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching. Scand J Gastroenterol. 1997;32:1140–6.
16. Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quattrini M. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol. 2003;36:225–9.
17. Pellini B, R B, Bresso F, Demarchi B, Bertolusso L, Sapone N, Rizzetto M, et al. Prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease: pilot study. Rev Esp Enferm Dig. 2010;102:675–66. author reply 676.
18. Triantafillidis JK, Gikas A, Apostolidis N, Merikas E, Mallas S, Peros G. The low prevalence of Helicobacter infection in patients with inflammatory bowel disease could be attributed to previous antibiotic treatment. Am J Gastroenterol. 2003;98:1213–4.
19. Castaño-Rodríguez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis. Gut. 2015 Oct 27. pii: gutjnl-2015-310545. doi: 10.1136/gutjnl-2015-310545. [Epub ahead of print]
20. Roka K, Ruma F, Stefanelli K, Panayotou I, Kopsidas G, Choularas G. The value of focally enhanced gastritis in the diagnosis of pediatric inflammatory bowel diseases. J Crohns Colitis. 2013;7:797–802.
21. Sonnenberg A, Melton SD, Genta RM. Frequent occurrence of gastritis and duodenitis in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:39–44.
22. Halme I, Kärkkäinen P, Rautelin H, Kosunen TU, Simponen P. High frequency of Helicobacter negative gastritis in patients with Crohn’s disease. Gut. 1996;38:789–83.
23. Santor BB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407.
24. Arnold IC, Hitzler I, Muller A. The immunomodulatory properties of Helicobacter pylori confer protection against allergic and chronic inflammatory disorders. Front Cell Infect Microbiol. 2012;2:10.
25. Shrot S, Konen E, Hertz M, Amitai MM. Magnetic resonance enterography: 4 years experience in a tertiary medical center. Isr Med Assoc J. 2011;13(3):172–7.
26. Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Gótz M, Katsanos KH, Kießlich R, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:1018–9.
27. Feng L, Wen MY, Zhu YY, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016 May-Jun;23(3):e880–93.
28. Samra Z, Shmueli H, Niv Y, Dinari G, Passaro DJ, Geler A, et al. Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefoxime. J Antimicrob Chemother. 2002;49:1023–6.
29. Tepel B, Vujasinovic M, Seruga M, Stefanovic M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol. 2016;28:766–73.
30. Kim JS, Kim BW, Hong SJ, Kim JI, Shin KN, Kim JH, et al. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial.Gut Liver. 2016 Apr 28. doi: 10.5009/gnl15470. [Epub ahead of print]
31. Li KC, Hui WM, Wong BC, Hu WH, Lam SK. Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. Aliment Pharmacol Ther. 2000;14:1071–6.